The Evolution of Alzheimer's & Dementia Care: A Personalized Approach
Neurologist and psychiatrist Gayatri Devi joins Peter Attia to explain why Alzheimer's and other dementias are spectrum conditions rather than all-or-nothing diseases. She describes a highly personalized approach to diagnosis and care, the promise and risks of new anti-amyloid drugs, and why early attention to inflammation may reshape how we think about brain health.
Overview
In this nearly two-hour conversation, Gayatri Devi — board-certified in neurology, psychiatry and several related fields — shares how her understanding of dementia has evolved over three decades of practice. She frames Alzheimer's disease as a spectrum condition that presents very differently from person to person, shaped by brain reserve, comorbidities and the region of the brain most affected.
Devi walks through the pathological cascade — from early neuroinflammation to amyloid plaques and tau tangles — and explains why intervening decades before symptoms could matter. She discusses the emerging role of viruses, gum health and estrogen in brain aging, and why women appear to face higher risk. Much of the discussion centers on the new anti-amyloid antibodies, lecanemab and donanemab, their modest measured benefits, serious imaging-related risks, and her cautious “low and slow” approach in high-risk carriers.
Devi also covers blood-based biomarkers, the pitfalls of testing people without symptoms, and long-standing tools like cholinesterase inhibitors and transcranial magnetic stimulation. She closes with the belief that changed her most: that some patients with Alzheimer's can genuinely improve, and that the future lies in nuanced, individualized care.
Key quotes
5I feel like I'm in the field now almost as if I was an infectious disease doctor practicing before and after penicillin was discovered.
This person is at stage zero as far as their ability to communicate, but maybe in memory they're at a stage three or four.
Names are inorganic bytes of information. Our brain is trained to remember things organically.
I never thought that patients with Alzheimer's could get better — ever.
Each person with Alzheimer's has their own private version of Alzheimer's that is different from everyone else who has the disease.
Key ideas
9Dementia is a spectrum, not all-or-nothing
Devi argues that dementias, and Alzheimer's in particular, span from very mild, stable impairment to rapid decline. Recognizing this spectrum reshapes how clinicians understand and manage each patient.
How Alzheimer's is defined
Alzheimer's is a progressive loss of synaptic connectivity driven by amyloid plaques and tau tangles, and — increasingly recognized — inflammation in the brain's supporting cells.
Inflammation may come first
Long thought to begin with amyloid, the cascade may actually start with inflammatory changes decades earlier. This suggests anti-inflammatory living from one's 30s and 40s could matter.
Infections and gum health may play a role
Shingles vaccination, suppression of herpes viruses and good dental health are all linked to lower dementia risk, likely through shared inflammatory pathways.
Diagnosis is rigorous and personalized
Devi uses hours of cognitive testing, brain imaging, blood-flow studies and biomarkers, because highly intelligent patients can mask significant pathology through cognitive reserve.
Stage by domain, not overall
Rather than assigning one overarching stage, she stages patients separately across domains such as memory, language and communication, which she finds far more informative.
Women appear to face higher, distinct risk
Loss of estrogen, cardiovascular survival patterns and immune differences may raise women's risk, and menopause-related cognitive changes can closely mimic early Alzheimer's.
Anti-amyloid drugs clear plaque but carry risk
Lecanemab and donanemab remove amyloid with only small measured clinical gains and real risks of brain swelling and bleeding, especially in people carrying two copies of APOE4.
Alzheimer's is not always a one-way street
After decades of practice, Devi came to believe that some patients genuinely improve with treatment — a view that upended the conventional teaching of inexorable decline.
Practical takeaways
7- 1
Brain health starts early 8:17
The conversation highlights that brain-protective, anti-inflammatory lifestyle habits may matter as early as one's 30s and 40s.
- 2
Everyday inflammation adds up 12:26
Dental health and managing common infections are discussed as underappreciated contributors to long-term brain wellness.
- 3
One label rarely tells the whole story 23:28
Because most people have mixed brain changes, a nuanced picture across many domains is more useful than a single diagnostic label.
- 4
Forgetting names is usually normal 27:35
Devi reassures that difficulty recalling names is expected; the brain simply isn't built to store endless made-up labels.
- 5
Menopause and brain fog are worth understanding 33:06
Cognitive changes around menopause can look like early dementia and are often addressable, making informed conversations valuable.
- 6
Staying mentally engaged matters 1:42:04
Targeted brain exercises and staying functionally engaged are described as meaningful ways to support brain resilience.
- 7
Personalized care is the direction of travel 1:57:12
The overarching message is that brain health is highly individual, and one-size-fits-all thinking misses what matters most.
Topics & chapters
15Meet Gayatri Devi
Introduction to a neurologist and psychiatrist specializing in memory disorders.
Dementia as a spectrum
Why dementias range from mild and stable to rapidly progressive.
Defining Alzheimer's and its subtypes
Dementia as an umbrella term and the plaques, tangles and inflammation that define Alzheimer's.
The pathological cascade
The possible order of inflammation, amyloid and tau, and the case for very early intervention.
Viruses, vaccines and gum health
How infections and inflammation may shape long-term dementia risk.
How a patient is evaluated
Devi's multi-day, rigorous testing and imaging workup.
Building a diagnosis, staging by domain
Piecing results together and her aversion to single-stage labels.
Why we forget names
The neuroscience of memory and reassurance about everyday lapses.
Sex differences and menopause
Why women appear to face higher risk and the role of estrogen.
Blood biomarkers and screening
The promise and pitfalls of testing, especially in people without symptoms.
Anti-amyloid antibodies and ARIA
Benefits, imaging-related risks and her cautious low-and-slow protocol.
Older tools: cholinesterase inhibitors, TMS and GLP-1s
Longstanding treatments, brain stimulation and metabolic health.
Vascular and Lewy body dementia
How these conditions present, overlap and are diagnosed.
Menopause, hormones and brain exercises
Hormone considerations and targeted mental activity for cognitive resilience.
What changed her mind, and the future
Why she now believes patients can improve, and where the field is heading.